...

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >P53 expression & Ki-67 labeling index as predictors for recurrence in ER positive breast cancer postmenopausal patients treated with adjuvant aromatase inhibitor

【24h】

P53 expression & Ki-67 labeling index as predictors for recurrence in ER positive breast cancer postmenopausal patients treated with adjuvant aromatase inhibitor

机译：P53表达和Ki-67标记指数可预测经芳香化酶抑制剂辅助治疗的ER阳性绝经后乳腺癌患者的复发

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第2期|共1页
作者
Abdelhalim I.; Elsadda W.; Elebrashi M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P53 expression & Ki-67 labeling index as predictors for recurrence in ER positive breast cancer postmenopausal patients treated with adjuvant aromatase inhibitor [J] . Abdelhalim I., Elsadda W., Elebrashi M. European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Suppla2期

机译：P53表达和Ki-67标记指数可预测经芳香化酶抑制剂辅助治疗的ER阳性绝经后乳腺癌患者的复发
2. p53 accumulation is a strong predictor of recurrence in estrogen receptor‐positive breast cancer patients treated with aromatase inhibitors [J] . Emi Takakuwa, Kanako C. Hatanaka, Kiichiroh Nakano, Cancer science. . 2014,第1期

机译：p53积累是用芳香化酶抑制剂治疗的雌激素受体阳性乳腺癌患者复发的有力预测指标
3. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone [J] . GnantM., FilipitsM., GreilR., Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第2期

机译：临床病理风险有限的受体阳性乳腺癌患者的远处复发预测：使用ABCSG-8试验的1478名绝经后仅接受辅助内分泌治疗的患者中使用PAM50复发风险评分
4. Bone Density Changes during Adjuvant Aromatase Inhibitor Treatment in Breast Cancer Patients: Single Centre Experience [C] . World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：乳腺癌患者辅助芳香化酶抑制剂治疗期间的骨密度变化：单中心经验。
5. The Genetics of Aromatase Inhibitor-related Phenotypes in Postmenopausal Women with ER+ Breast Cancer [D] . Dudenkov, Tanda Tosia Murray. 2017

机译：ER +乳腺癌绝经后妇女芳香酶抑制剂相关表型的遗传
6. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors [O] . Mitsugu Yamamoto, Mitsuchika Hosoda, Kiichiroh Nakano, 2014

机译：p53积累是用芳香化酶抑制剂治疗的雌激素受体阳性乳腺癌患者复发的有力预测指标
7. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors [O] . Yamamoto, Mitsugu, Hosoda, Mitsuchika, Nakano, Kiichiroh, 2014

机译：p53积累是用芳香化酶抑制剂治疗的雌激素受体阳性乳腺癌患者复发的有力预测指标

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号